HIV associated high-risk HPV infection among Nigerian women

BMC Infectious Diseases

Clement A Adebamowo²  Cosette M Wheeler¹  Richard Offiong³  Olayinka B Olaniyan⁵  Eileen O Dareng⁴  Ayotunde O Famooto⁴  Maryam Al-Mujtaba⁴  Sally N Akarolo-Anthony⁴ 

[1] Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA;Institute of Human Virology and Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA;University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria;Office of Strategic Information and Research Department, Institute of Human Virology Nigeria, 252 Herbert Macaulay Way, Abuja, Nigeria;Department of Obstetrics and Gynecology, National Hospital, Abuja, Nigeria

关键词: Nigeria;    HPV;    HIV;   

Others  :  1145548
DOI  :  10.1186/1471-2334-13-521

 received in 2013-07-08, accepted in 2013-10-29,  发布年份 2013

【 摘 要 】

Background

In developed countries, the incidence of cervical cancer has remained stable in HIV+ women but the prevalence and multiplicity of high-risk HPV (hrHPV) infection, a necessary cause of cervical cancer, appears different comparing HIV+ to HIV- women. Little is known about HIV and HPV co-infection in Africa.

Methods

We enrolled women presenting at our cervical cancer screening program in Abuja, Nigeria between April and August 2012, and collected information on demographic characteristics, risk factors of HPV infection and samples of exfoliated cervical cells. We used Roche Linear Array HPV Genotyping Test® to characterize prevalent HPV and logistic regression models to estimate the association between HIV and the risk of hrHPV infection.

Results

There were 278 participants, 54% (151) were HIV+, 40% (111) were HIV-, and 6% (16) had unknown HIV status. Of these, data from 149 HIV+ and 108 HIV- women were available for analysis. The mean ages (±SD) were 37.6 (±7.7) years for HIV+ and 36.6 (±7.9) years for HIV- women (p-value = 0.34). Among the HIV+ women, HPV35 (8.7%) and HPV56 (7.4%) were the most prevalent hrHPV, while HPV52 and HPV68 (2.8%, each) were the most prevalent hrHPV types among HIV- women. The multivariate prevalence ratio for any hrHPV and multiple hrHPV infections were 4.18 (95% CI 2.05 – 8.49, p-value <0.0001) and 6.6 (95% CI 1.49 – 29.64, p-value 0.01) respectively, comparing HIV + to HIV- women, adjusted for age, and educational level.

Conclusions

HIV infection was associated with increased risk of any HPV, hrHPV and multiple HPV infections. Oncogenic HPV types 35, 52, 56 and 68 may be more important risk factors for cervical pre-cancer and cancer among women in Africa. Polyvalent hrHPV vaccines meant for African populations should protect against other hrHPV types, in addition to 16 and 18.

【 授权许可】

   
2013 Akarolo-Anthony et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
• [2]Human Papilloma Virus. http://www.cdc.gov/STD/HPV/STDFact-HPV.htm webcite
• [3]de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004, 324:17-27.
• [4]Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
• [5]Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, et al.: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366:991-998.
• [6]Schiffman M, Clifford G, Buonaguro FM: Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009, 4:8. BioMed Central Full Text
• [7]Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al.: A review of human carcinogens–Part B: biological agents. Lancet Oncol 2009, 10:321-322.
• [8]Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM: Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128:927-935.
• [9]Bodily J, Laimins LA: Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol 2011, 19:33-39.
• [10]Smith JS, Melendy A, Rana RK, Pimenta JM: Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008, 43:S5-25. S25 e21-41
• [11]Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford GM: Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131:2349-2359.
• [12]Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632.
• [13]Denny L, Anorlu R: Cervical cancer in Africa. Cancer Epidemiol Biomarkers Prev 2012, 21:1434-1438.
• [14]Louie KS, de Sanjose S, Mayaud P: Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop Med Int Health 2009, 14:1287-1302.
• [15]Safaeian M, Kiddugavu M, Gravitt PE, Gange SJ, Ssekasanvu J, Murokora D, Sklar M, Serwadda D, Wawer MJ, Shah KV, Gray R: Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev 2008, 17:1300-1307.
• [16]Veldhuijzen NJ, Braunstein SL, Vyankandondera J, Ingabire C, Ntirushwa J, Kestelyn E, Tuijn C, Wit FW, Umutoni A, Uwineza M, et al.: The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda. BMC Infect Dis 2011, 11:333. BioMed Central Full Text
• [17]Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001, 357:1831-1836.
• [18]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide. In Book GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide (Editor ed.^eds.). City: International Agency for Research on Cancer; 2010.
• [19]Klint A, Tryggvadottir L, Bray F, Gislum M, Hakulinen T, Storm HH, Engholm G: Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol 2010, 49:632-643.
• [20]Mbulaiteye SM, Bhatia K, Adebamowo C, Sasco AJ: HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data. Infect Agent Cancer 2011, 6:16. BioMed Central Full Text
• [21]Parkin DM, Ferlay J, Hamdi-Cherif M, Sitas F, Thomas JO, Wabinga H, Whelan SL: Cancer in Africa: epidemiology and prevention. Lyon: IARCPress; 2003.
• [22]Ndiaye C, Alemany L, Ndiaye N, Kamate B, Diop Y, Odida M, Banjo K, Tous S, Klaustermeier JE, Clavero O, et al.: Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: could HIV explain the differences? Trop Med Int Health 2012, 17:1432-1440.
• [23]Levi JE, Kleter B, Quint WG, Fink MC, Canto CL, Matsubara R, Linhares I, Segurado A, Vanderborght B, Neto JE, Van Doorn LJ: High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol 2002, 40:3341-3345.
• [24]Luque AE, Jabeen M, Messing S, Lane CA, Demeter LM, Rose RC, Reichman RC: Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis 2006, 194:428-434.
• [25]Blossom DB, Beigi RH, Farrell JJ, Mackay W, Qadadri B, Brown DR, Rwambuya S, Walker CJ, Kambugu FS, Abdul-Karim FW, et al.: Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. J Med Virol 2007, 79:758-765.
• [26]Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, Huh WK, Lyon MD, Stringer JS, Parham GP: Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer 2007, 96:1480-1483.
• [27]Jaquet A, Horo A, Charbonneau V, Ekouevi DK, Roncin L, Toure B, Coffie P, Minga A, Sasco AJ, Garrigue I, et al.: Cervical human papillomavirus and HIV infection in women of child-bearing age in Abidjan, Cote d’Ivoire, 2010. Br J Cancer 2012, 107:556-563.
• [28]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
• [29]Jedy-Agba E, Curado MP, Ogunbiyi O, Oga E, Fabowale T, Igbinoba F, Osubor G, Otu T, Kumai H, Koechlin A, et al.: Cancer incidence in Nigeria: a report from population-based cancer registries. Cancer Epidemiol 2012, 36:e271-278.
• [30]Cooksley CD, Hwang LY, Waller DK, Ford CE: HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data. Int J STD AIDS 1999, 10:795-802.
• [31]Castle PE, Sadorra M, Garcia F, Holladay EB, Kornegay J: Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology. J Clin Microbiol 2006, 44:3915-3917.
• [32]Coutlee F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, Boyle S, Hankins C, Vezina S, Cote P, et al.: Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol 2006, 44:1998-2006.
• [33]Stevens MP, Rudland E, Garland SM, Tabrizi SN: Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J Clin Microbiol 2006, 44:2428-2433.
• [34]van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ: Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol 2006, 44:3122-3129.
• [35]Stevens MP, Garland SM, Tabrizi SN: Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test. J Clin Microbiol 2008, 46:3813-3816.
• [36]Franklin JD, Guidry A, Brinkley JF: A partnership approach for electronic data capture in small-scale clinical trials. J Biomed Inform 2011, 44(Supplement 1):S103-S108.
• [37]Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009, 42:377-381.
• [38]McKenzie ND, Kobetz EN, Hnatyszyn J, Twiggs LB, Lucci JA 3rd: Women with HIV are more commonly infected with non-16 and −18 high-risk HPV types. Gynecol Oncol 2010, 116:572-577.
• [39]Bollen LJ, Chuachoowong R, Kilmarx PH, Mock PA, Culnane M, Skunodom N, Chaowanachan T, Jetswang B, Neeyapun K, Asavapiriyanont S, et al.: Human papillomavirus (HPV) detection among human immunodeficiency virus-infected pregnant Thai women: implications for future HPV immunization. Sex Transm Dis 2006, 33:259-264.
• [40]De Vuyst H, Steyaert S, Van Renterghem L, Claeys P, Muchiri L, Sitati S, Vansteelandt S, Quint W, Kleter B, Van Marck E, Temmerman M: Distribution of human papillomavirus in a family planning population in nairobi, kenya. Sex Transm Dis 2003, 30:137-142.
• [41]Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M, Hutchinson M, Wacholder S, Harford J, Soliman AS, et al.: The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer 2012, 130:2111-2117.
• [42]Musa J, Taiwo B, Achenbach C, Olugbenga S, Berzins B, Sagay AS, Idoko JA, Kanki PJ, Murphy RL: High-risk human papillomavirus among HIV-infected women with normal cervical cytology: a pilot study in Jos, Nigeria. Arch Gynecol Obstet 2013.